In bacterial vaginosis, is treatment of the sexual partner required?

Partner Treatment for Bacterial Vaginosis

No, routine treatment of sexual partners is NOT recommended for bacterial vaginosis based on established guidelines, though groundbreaking 2025 evidence suggests combined oral and topical male partner treatment may reduce recurrence rates. 1, 2

Current Guideline Recommendations

The CDC guidelines explicitly state that routine treatment of sex partners is not recommended for BV 1, 2. This recommendation is based on clinical trials showing that:

• Treatment of male partners does not influence the woman's response to initial therapy
• Partner treatment does not affect relapse or recurrence rates
• Male sex partners are typically asymptomatic

This represents the standard of care that has been consistent across multiple guideline iterations from 1993 through 2006.

Critical New Evidence (2025)

However, the StepUp trial 3 fundamentally challenges this paradigm. This randomized controlled trial demonstrated:

• 35% recurrence rate with combined partner treatment vs. 63% recurrence with standard care alone
• Absolute risk reduction of 2.6 recurrences per person-year (95% CI: -4.0 to -1.2; P<0.001)
• The trial was stopped early due to clear superiority of partner treatment

Key Distinction in the StepUp Protocol

The StepUp trial used combined oral AND topical therapy for male partners:

• Metronidazole 400 mg orally twice daily for 7 days
• 2% clindamycin cream applied to penile skin twice daily for 7 days

This differs from all previous trials that used oral therapy alone 4.

Evidence Synthesis

A 2026 meta-analysis 4 clarifies the discrepancy:

• Oral monotherapy for male partners: No benefit (RR = 1.08 when excluding StepUp trial)
• Combined oral + topical therapy: Significant reduction in recurrence (only the StepUp trial used this approach)

Another 2026 network meta-analysis 5 confirms partner treatment reduces recurrence (IRR = 0.76,95% CI: 0.60-0.98; moderate-certainty evidence).

Clinical Application Framework

For Initial BV Episodes:

• Treat the woman only per standard guidelines 1, 2
• Partner treatment is not indicated

For Recurrent BV:

Consider combined oral and topical male partner treatment based on:

Indications for partner treatment:

• Documented recurrent BV (≥2 episodes within 6 months)
• Monogamous heterosexual relationship
• Patient preference after counseling about emerging evidence
• Willingness of male partner to comply with 7-day dual therapy

Partner treatment regimen (based on StepUp trial):

• Metronidazole 400 mg orally twice daily × 7 days
• 2% clindamycin cream to penile skin twice daily × 7 days
• Woman receives standard first-line BV treatment

Expected adverse effects in treated men:

• Nausea
• Headache
• Metallic taste
• Generally well-tolerated 3

Important Caveats

1. The StepUp trial is a single study from Australia—generalizability to broader populations requires confirmation 6

2. Current U.S. guidelines have not yet incorporated this evidence, though ACOG issued a 2025 Clinical Practice Update acknowledging the new data 7

3. Previous trials using oral therapy alone consistently showed no benefit 4—the topical component appears critical

4. This applies only to heterosexual couples—no data exist for female-female partnerships

5. Insurance coverage may be problematic as this represents off-label use not yet in formal guidelines

Practical Counseling Points

When discussing with patients:

• Standard care remains treatment of the woman only
• Emerging evidence suggests sexual transmission may contribute to recurrence
• Combined partner treatment (oral + topical) shows promise for recurrent cases
• This represents evolving practice ahead of formal guideline updates
• Shared decision-making is appropriate for recurrent BV

The evidence strongly suggests we are witnessing a paradigm shift in BV management, but clinicians should recognize this represents cutting-edge practice that has not yet been incorporated into formal U.S. treatment guidelines 6, 7, 8.